No annual revenue total was found in Corvus Pharmaceuticals, Inc.'s SEC filings.
Corvus Pharmaceuticals, Inc. (CRVS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$33.0 million. As of Sep 30, 2026 it held $202.9 million in cash and investments and $632,000 in total debt.
Revenue
—
Net income (TTM)
$-64.31M
-326.6% vs year-ago TTM
Operating cash flow (TTM)
$-47.18M
-47.1% vs year-ago TTM
Free cash flow (TTM)
$-47.94M
-48.8% vs year-ago TTM
EPS (TTM)
$-0.72
-262.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
83.99M
+23.3% vs prior year
Net cash
$202.31M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRVS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1626971
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2021 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$43.0M | -$27.5M | -$23.4M | -$32.6M | -$38.6M |
| Net income | -$15.3M | -$62.3M | -$27.0M | -$41.3M | -$43.2M |
| Diluted EPS | -$0.53 | -$1.02 | -$0.56 | -$0.89 | -$1.03 |
| Operating cash flow | -$32.8M | -$25.4M | -$23.9M | -$27.0M | -$36.7M |
| Free cash flow | -$33.0M | — | -$24.0M | -$27.3M | -$36.7M |
| Total assets | $71.1M | $68.9M | $45.6M | $68.2M | $109.5M |
| Total liabilities | $9.9M | $36.3M | $6.9M | $12.1M | $12.3M |
| Stockholders' equity | $61.2M | $32.6M | $38.7M | $56.1M | $97.2M |
| Cash and investments | $56.8M | $52.0M | $27.1M | $42.3M | $69.5M |
| Total debt | $937,000 | $1.1M | $1.4M | $2.6M | $3.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 22, 2026 | Jul 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
All 583 Corvus Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.